



Boehringer  
Ingelheim

1652 100 SEP 20 10 09

Dockets Management Branch (HFA-305)  
Food and Drug Administration  
5630 Fishers Lane  
Rm 1061  
Rockville, MD 20852

Boehringer Ingelheim  
Pharmaceuticals, Inc.

September 19, 2000

**Docket # OOD-1306, Comments on the Draft Guidance on Content & Format of the Adverse Reactions Section of Labeling for Human Prescription Drugs & Biologics**

Dear Sir/Madame,

Per the June 21, 2000 Federal Register Notice, Boehringer Ingelheim Pharmaceuticals, Inc. is now submitting comments to Draft Guidance on Content & Format of the Adverse Reactions Section of Labeling for Human Prescription Drugs & Biologics. We believe that this labeling guidance on Adverse Reactions is helpful to the industry and supports the ICH and CIOMS international initiatives for appropriate dissemination of safety data. BIPI's underlying philosophical principle regarding labeling is consistent with the Agency's approach, which could be summarized as evidence-based worldwide consistent labeling of adverse reactions, with obvious recognition of the importance of scientific data reviews from the public health perspective.

Tacy Pack  
Telephone 203-798-5545  
Telefax 203-791-6262  
E-Mail

900 Ridgebury Rd/P.O. Box 368  
Ridgefield, CT 06877-0368  
Telephone (203) 798-9988

From the scientific perspective and particularly in line with ICH/CIOMS activities, BIPI requests that this guidance provide additional FDA insight into the assessment of adverse events (AEs) and the potential standards and criteria to characterize an AE as an adverse reaction (AR) and when to include it in a company's core data sheets. The FDA language is loosely written and contains internal inconsistencies that could create variation of US labeling both from the scientific assessment of the available data and company's core data sheet listing of ARs. It appears that the only valid approach is that all ARs are appropriately included in the package insert (PI). All AEs are evaluated based on the available information and judged by the company in conjunction with review and discussion with FDA for appropriate inclusion in the label. Inclusion in the PI should be scientifically driven with an obvious eye to the public health. Companies should have the right to exclude "events" (not "reactions") clearly not related to the drug which may show an increase in the number reported when compared to placebo but which do not represent a serious event with no pharmacological connection, similar to this guidance's section on less common AEs. Specifically, this comment does not relate to the recommended handling

OOD-1306


C 12

of “less common events”, but rather addresses adverse events when relatively higher incidences that are judged not clinically important or drug related.

BIPI also proposes that the Agency strive toward more consistency with the newly revised European AE section labeling (European Commission “A guideline on Summary of Product Characteristics” December 1999).

Finally, we also propose that this guidance mention adverse events that occur following withdrawal of drug when they are relevant, when there is a distinct relationship, and when it is specific to withdrawal symptomatology.

Best regards,



Tacy Pack  
Sr. Associate Director  
DRA Product Labeling

800

Packet #000-1306, Comments on 1  
**FedEx** Section of Labeling  
 USA Airbill Tracking Number

8221 1404 3708

RECIPIENT: PEEL HERE

**1 From** This portion can be removed for Recipient's records.

Date 9/20/00 FedEx Tracking Number 822114043708

Sender's Name Tacy Pack Phone 203 798-4538

Company BOEHRINGER INGELHEIM PHARM

Address 900 RIDGEBURY RD Dept./Floor/Suite/Room

City RIDGEFIELD State CT ZIP 06877

**2 Your Internal Billing Reference** 6216

**3 To**

Recipient's Name \_\_\_\_\_ Phone \_\_\_\_\_

Company Dockets Management Branch (HFA-305)

Address Food and Drug Administration

Address 5630 Fishers Lane We cannot deliver to P.O. boxes or P.O. ZIP codes.

Room 1061 Dept./Floor/Suite/Room

City Rockville State MD ZIP 20852



Content & Format of the Adverse Reactions  
 Drugs & Biologics

Form ID No 0215 Recipient's Copy

**4a Express Package Service** Packages up to 150 lbs. Delivery commitment may be later in some areas.

☒ FedEx Priority Overnight Next business morning ☐ FedEx Standard Overnight Next business afternoon ☐ FedEx First Overnight Earliest next business morning delivery to select locations

☐ FedEx 2Day\* Second business day ☐ FedEx Express Saver\* Third business day \*FedEx Envelope/Letter Rate Not available Minimum charge: One pound rate

**4b Express Freight Service** Packages over 150 lbs. Delivery commitment may be later in some areas.

☐ FedEx 1Day Freight\* Next business day ☐ FedEx 2Day Freight Second business day ☐ FedEx 3Day Freight Third business day

\* Call for Confirmation. \* Declared value limit \$500

**5 Packaging**

☒ FedEx Envelope/Letter\* ☐ FedEx Pak\* ☐ Other Pkg. Includes FedEx Box, FedEx Tube, and customer pkg.

**6 Special Handling** Include FedEx address in Section 3.

☐ SATURDAY Delivery Available for FedEx Priority Overnight and FedEx 2Day to select ZIP codes ☐ SUNDAY Delivery Available for FedEx Priority Overnight to select ZIP codes ☐ HOLD Weekday at FedEx Location Not available with FedEx First Overnight ☐ HOLD Saturday at FedEx Location Available for FedEx Priority Overnight and FedEx 2Day to select locations

Does this shipment contain dangerous goods? One box must be checked.

☐ No ☐ Yes As per attached Shipper's Declaration ☐ Yes Shipper's Declaration not required ☐ Dry Ice Dry Ice, 3, UN 1845 x kg ☐ Cargo Aircraft Only

Dangerous Goods cannot be shipped in FedEx packaging.

**Payment Bill to:** Enter FedEx Acct. No. or Credit Card No. below.

☒ Sender Acct. No. in Section 3 will be billed. ☐ Recipient ☐ Third Party ☐ Credit Card ☐ Cash/Check ☐ Obtain Recip. Acct. No.

Total Packages \_\_\_\_\_ Total Weight \_\_\_\_\_ Total Charges \_\_\_\_\_

Credit Card Auth. \_\_\_\_\_

**8 Release Signature** Sign to authorize delivery without obtaining signature.

By signing you authorize us to deliver this shipment without obtaining a signature and agree to indemnify and hold us harmless from any resulting claims.

Questions? Call 1-800-Go-FedEx (800-463-3339)

Visit our Web site at [www.fedex.com](http://www.fedex.com)

SRS 420 Rev. Date 7/00 Part #1559125 © 1994-2000 FedEx PRINTED IN U.S.A.

402

0150506340